← Leaderboards
Christopher L Karp
Children'S Hospital Med Ctr (Cincinnati)
$9,882,745
Attributed
$10,064,486
Total exposure
14
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–11$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$10,064,486 · 14
By mechanism
R01$8,091,413 · 7
R21$885,748 · 2
R41$463,483 · 2
P30$406,156 · 1
R29$215,186 · 1
R13$2,500 · 1
Top collaborators
- Julio Aliberti1 shared
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsInflammationInfectionMediatingMolecularCellsClinical ResearchInflammatory ResponseMicrobialLeadHuman SubjectImmune ResponseIn VitroIn VivoImmunotherapyLeishmania (Genus)In Vivo ModelMacrophageProductionPathogenInterleukin 12HandCytokinePathogenesis
Grant awards (40)
Allergenicity resulting from functional mimicry of the TLR complex$376,041
R01 · FY2011 · AI · contact PI
Allergenicity resulting from functional mimicry of the TLR complex$391,743
R01 · FY2010 · AI · contact PI
Immunobiology of IFRD1, a gene modifying CF lung disease$384,813
R01 · FY2010 · HL · contact PI
Regulation of TLR Signaling and Innate Immunity by RP105$364,197
R01 · FY2010 · AI · contact PI
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4$85,625
P30 · FY2010 · AR · contact PI
Lipid Mediators and Dysregulated Inflammation in CF$418,512
R01 · FY2009 · HL · contact PI
Immunobiology of IFRD1, a gene modifying CF lung disease$391,600
R01 · FY2009 · HL · contact PI
Regulation of TLR Signaling and Innate Immunity by RP105$367,875
R01 · FY2009 · AI · contact PI
Novel immune-based therapy for leishmaniasis and tuberculosis$363,483
R41 · FY2009 · AI · contact PI
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4$85,418
P30 · FY2009 · AR · contact PI
Lipid Mediators and Dysregulated Inflammation in CF$400,849
R01 · FY2008 · HL · contact PI
Regulation of TLR Signaling and Innate Immunity by RP105$367,875
R01 · FY2008 · AI · contact PI
Role of Regulatory T cells in Leishmania major infection$277,189
R01 · FY2008 · AI · contact PI
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4$87,788
P30 · FY2008 · AR · contact PI
Lipid Mediators and Dysregulated Inflammation in CF$399,830
R01 · FY2007 · HL · contact PI
Regulation of TLR Signaling and Innate Immunity by RP105$375,000
R01 · FY2007 · AI · contact PI
Role of Regulatory T cells in Leishmania major infection$282,558
R01 · FY2007 · AI · contact PI
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4$72,825
P30 · FY2007 · AR · contact PI
Lipid Mediators and Dysregulated Inflammation in CF$402,443
R01 · FY2006 · HL · contact PI
Role of Regulatory T cells in Leishmania major infection$290,997
R01 · FY2006 · AI · contact PI
Regulation of Toll-like Receptor signaling by RP105$218,248
R21 · FY2006 · AI · contact PI
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4$74,500
P30 · FY2006 · AR · contact PI
Lipid Mediators and Dysregulated Inflammation in CF$413,286
R01 · FY2005 · HL
Role of Regulatory T cells in Leishmania major infection$298,000
R01 · FY2005 · AI
Regulation of Toll-like Receptor signaling by RP105$223,500
R21 · FY2005 · AI
Novel lipid -based therapies for cystic fibrosis$100,000
R41 · FY2004 · HL
IFN BETA AND IMMUNOREGUALTION IN MULTIPLE SCLEROSIS$259,000
R01 · FY2003 · NS
Ebola Virus: Immunopathogenesis and Therapy$222,000
R21 · FY2003 · AI
HEPATITIS C: IFN-ALPHA, IL-12 AND IMMUNOREGULATION$206,676
R01 · FY2003 · DK
IFN BETA AND IMMUNOREGUALTION IN MULTIPLE SCLEROSIS$259,000
R01 · FY2002 · NS
Ebola Virus: Immunopathogenesis and Therapy$222,000
R21 · FY2002 · AI
HEPATITIS C: IFN-ALPHA, IL-12 AND IMMUNOREGULATION$200,655
R01 · FY2002 · DK
IFN BETA AND IMMUNOREGUALTION IN MULTIPLE SCLEROSIS$259,000
R01 · FY2001 · NS
HEPATITIS C: IFN-ALPHA, IL-12 AND IMMUNOREGULATION$194,814
R01 · FY2001 · DK
IMMUNOSUPPRESSION IN MEASLES--THE ROLE OF IL 12 AND CD46$109,168
R29 · FY2001 · AI
CONFERENCE ON MACROPHAGE ACTIVATION AND DEACTIVATION$2,500
R13 · FY2001 · AI
IFN BETA AND IMMUNOREGUALTION IN MULTIPLE SCLEROSIS$246,761
R01 · FY2000 · NS
HEPATITIS C: IFN-ALPHA, IL-12 AND IMMUNOREGULATION$189,140
R01 · FY2000 · DK
IMMUNOSUPPRESSION IN MEASLES--THE ROLE OF IL 12 AND CD46$106,018
R29 · FY2000 · AI
IFN BETA AND IMMUNOREGUALTION IN MULTIPLE SCLEROSIS$73,559
R01 · FY2000 · NS